Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases.
作者信息
Held H, Eisert R, von Oldershausen H F
出版信息
Arzneimittelforschung. 1973 Dec;23(12):1801-7.
PMID:4801689
Abstract
摘要
相似文献
1
Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases.格列嘧啶（甘氨二嗪）和甲苯磺丁脲在急慢性肝病中的药代动力学
Arzneimittelforschung. 1973 Dec;23(12):1801-7.
2
[Pharmacokinetics of tolbutamide and glycodiazine in liver and kidney diseases].[甲苯磺丁脲和格列本脲在肝脏和肾脏疾病中的药代动力学]
Verh Dtsch Ges Inn Med. 1973;79:1220-3.
3
[Comparison of the beta-cytotropic effect of glymidine sodium (glycodiazine), glucagon, and isopropylnoradrenaline in rats].[大鼠中格列嘧啶钠（甘氨二嗪）、胰高血糖素和异丙去甲肾上腺素的β-亲细胞作用比较]
Arzneimittelforschung. 1973 Sep;23(9):1251-60.
4
Correlation between the activity of hepatic benzo (a) pyrene hydroxylase in human needle biopsies and the clearance of glymidine.
Hepatogastroenterology. 1980 Aug;27(4):266-70.
5
Effect of insulin and glycodiazine on the level of plasma free fatty acids in bilharzial (schistosomal) hepatic fibrosis.胰岛素和格列本脲对血吸虫性肝纤维化患者血浆游离脂肪酸水平的影响
J Trop Med Hyg. 1972 Jun;75(6):115-8.
6
[Inhibition of ketogenesis in liver tissue by tolbutamide and glycodiazine in vitro].甲苯磺丁脲和格列氮嗪对肝组织生酮作用的体外抑制
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1969;262(2):152-64.
7
8
Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.基于体外实验预测甲苯磺丁脲与多种磺胺类药物在人体内的药物相互作用。
Drug Metab Dispos. 2000 Apr;28(4):475-81.
9
Influence of some salicylates and sulfonamides on binding by albumin of SPC-703 and tolbutamide.某些水杨酸盐和磺胺类药物对SPC - 703及甲苯磺丁脲与白蛋白结合的影响。
Pol J Pharmacol Pharm. 1976;28(2):129-35.
引用本文的文献
1
Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.磺酰脲类降糖药的临床药理学：第2部分。
Drugs. 1981 Oct;22(4):295-320. doi: 10.2165/00003495-198122040-00003.
2
Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.磺酰脲类降糖药物的临床药代动力学
Clin Pharmacokinet. 1981 May-Jun;6(3):215-41. doi: 10.2165/00003088-198106030-00003.
3
Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.利福平治疗后通过增加己巴比妥和甲苯磺丁脲清除率来测定人体药物代谢的诱导情况。
Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):219-27. doi: 10.1007/BF00614021.
4
Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.通过增加己巴比妥和甲苯磺丁脲清除率来测定利福平对肝硬化或胆汁淤积患者药物代谢的刺激作用。
Eur J Clin Pharmacol. 1977 Apr 20;11(4):287-93. doi: 10.1007/BF00607679.
5
Disposition of valproic acid in patients with liver disease.丙戊酸在肝病患者中的处置情况。
Eur J Clin Pharmacol. 1978 Mar 17;13(1):55-60. doi: 10.1007/BF00606683.
6
Protein binding and kinetics of drugs in liver diseases.肝脏疾病中药物的蛋白结合与动力学
Clin Pharmacokinet. 1977 Jan-Feb;2(1):32-44. doi: 10.2165/00003088-197702010-00003.
7
[Decreased serum protein binding of glymidine in icteric liver disease and its partial correction with charcoal (author's transl].黄疸性肝病中格列嘧啶血清蛋白结合率降低及其用活性炭的部分纠正（作者译）
Klin Wochenschr. 1979 Jul 3;57(13):693-5. doi: 10.1007/BF01477670.
Zotero 插件